Search

Displaying results 2761 - 2770 of 4859 in total
  1. Drug

    Idarubicin

    go.drugbank.com/drugs/DB01177
    ApprovedInvestigational

    An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

  2. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    Thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, are associated with injury and dysregulation of microvascular endothelium and platelets. Evidence increasingly poin...

  3. Drug

    VP-14637

    go.drugbank.com/drugs/DB12195
    Investigational

    MDT-637 has been investigated for the treatment of Drug Safety.

  4. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    Its mechanism of action is still being investigated, but it is known that tetraethylammonium blocks autonomic ganglia, calcium- and voltage- activated potassium channels, and nicotinic acetylcholine receptors

  5. Drug

    Eletriptan

    go.drugbank.com/drugs/DB00216
    ApprovedInvestigational

    Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

  6. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    It also improves poor blood flow in the nerve tissue in cervical spondylosis and normalizes nerve function. … However, it was verified by Seoul National University Hospital in November of 2014 that the study on the efficacy of oral limaprost alfadex after surgery for cervical myelopathy was still ongoing.

  7. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. … Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel] and [tisagenlecleucel], it

  8. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes.

  9. Drug

    Sage oil

    go.drugbank.com/drugs/DB11199
    ApprovedNutraceutical

    It is found in cosmetics, personal care products and dietary supplements. … Essential oil has been traditionally used in medicine for the relief of pain and the treatment of inflammation and infections, as it is reported to exhibit carminative, antispasmodic, antiseptic, and astringent

  10. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    It is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis, and is a mixture of catechins and other green tea components. … In addition to the known catechin components, it also contains gallic acid, caffeine, and theobromine which together constitute about 2.5% of the drug substance.